iShares Core MSCI EAFE ETF vs Stryker Corporation — how do they compare? iShares Core MSCI EAFE ETF trades at $96.24 (market cap $189.19B), while Stryker Corporation trades at $278.7 (market cap $106.24B). The key difference: iShares Core MSCI EAFE ETF is the larger of the two by market cap, and Stryker Corporation pays a 1.27% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Stryker Corporation for 20 Days on average.
| IEFA | SYK | |
|---|---|---|
Market Cap | $189.19B | $106.24B |
Volume | 8,441,787 | 2,982,001 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $388.35 |
52-Week Low | $85.06 | $269.75 |
Typical Hold Time | 41 Days | 20 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $96.18, down 0.02% on the day, with a bearish technical outlook indicated by moving averages and oscillators. The ETF, managed by BlackRock, holds $196 billion in assets and focuses on developed markets outside North America. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower expense ratio relative to some peers, though performance has lagged behind certain total-world and emerging market funds over the past year.
The outlook for IEFA is clouded by technical weakness and competitive pressures, though its scale and cost efficiency offer stability. Key risks include concentration in developed markets, which may underperform during global growth shifts, and the impact of geopolitical tensions on international equities. Analyst sentiment is mixed, with the fund's defensive characteristics balancing against limited near-term catalysts.
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →